A Randomized Dose Ranging Study of Hexadecasaccharide Including Active Control, in Patients With Unstable Angina or Non-ST-Segment Elevation Myocardial Infarction Scheduled to Undergo Percutaneous Coronary Intervention (SHINE)

CompletadoFase 2ClinicalTrials.gov

ID: NCT00123565Tipo: INTERVENTIONALInicio: 1 de dic de 2004Fin estimado: 1 de may de 2007

Traducción no disponible, mostrando original

Resumen

The purpose of this study is to test whether SR123781A is a possible treatment for patients with acute coronary syndromes (heart attack) who are scheduled to undergo a percutaneous coronary intervention (PCI) within 48 hours after inclusion in the study. Two doses of SR123781A are currently tested, each in a group of about 180 patients per group to find which is the most adequate, versus heparin and glycoprotein IIbIIIa (GPIIBIIIA) antagonist.

Elegibilidad

Edad mínima: 21 YearsSexo: ALL

Criterios de inclusión

A person with a diagnosis of acute coronary syndrome who is scheduled to undergo a PCI within 48 hours.
A person who is of the legal age of 21, who is mentally competent, and who has signed a written informed consent

Criterios de exclusión

A person with known allergy or any contra-indication to active control.
A person who has received heparin during more than 48 hours before inclusion in the study.
A person treated with warfarin (oral anticoagulant).
A person with current bleeding or recognized increased risk of bleeding or history of intracranial hemorrhage.
A person who has had a stroke within the last 6 months.
A person with uncontrolled hypertension despite antihypertensive therapy.
A person with history of clinically significant reduction in blood platelets or neutrophils (white blood cells).
A person who has laboratory evidence of significantly reduced renal function or who is dependent on renal dialysis.
A person who has a coronary bypass performed during the previous month.
A pregnant or nursing woman or a woman of childbearing potential (before menopause) who does not have a negative pregnancy test and does not use a reliable method of birth control.
A person who has received any investigational treatment in the preceding month.

Intervenciones

drug

Hexadecasaccharide (SR123781A)

Ubicaciones

Sanofi-Aventis

Buenos Aires, Argentina

Patrocinadores

PrincipalSanofi

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

A Randomized Dose Ranging Study of Hexadecasaccharide Inc... | EligiMed